Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
07.08. | Tarsus targets 95,000-100,000 bottles for Q3 2025 amid accelerated XDEMVY launch momentum | 1 | Seeking Alpha | ||
06.08. | Tarsus Pharmaceuticals, Inc: Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements | 177 | GlobeNewswire (Europe) | Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded... ► Artikel lesen | |
06.08. | Tarsus Pharmaceuticals, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
06.08. | Tarsus Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
30.07. | Tarsus Pharmaceuticals, Inc: Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025 | 1 | GlobeNewswire (USA) | ||
18.06. | Tarsus Pharmaceuticals, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
09.06. | Tarsus Pharmaceuticals auf Goldman Sachs Konferenz: Fokus auf strategisches Wachstum | 3 | Investing.com Deutsch | ||
TARSUS PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
02.06. | Oppenheimer assumes Tarsus stock at outperform on strong sales | 1 | Investing.com | ||
27.05. | Tarsus Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) | 2 | Benzinga.com | ||
27.05. | H.C. Wainwright sets $72 target for Tarsus stock with Buy rating | 2 | Investing.com | ||
06.05. | 6 Analysts Assess Tarsus Pharmaceuticals: What You Need To Know | 2 | Benzinga.com | ||
02.05. | Tarsus Pharmaceuticals anticipates 85,000-90,000 XDEMVY bottles dispensed in Q2 2025 amid expanded DTC campaign | 1 | Seeking Alpha | ||
01.05. | Tarsus Pharmaceuticals, Inc. GAAP EPS of -$0.64, revenue of $78.3M | 3 | Seeking Alpha | ||
01.05. | Tarsus Pharmaceuticals, Inc: Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements | 605 | GlobeNewswire (Europe) | Generated $78.3 million in net product sales of XDEMVY®, an increase of 217% year over year and 18% over Q4 2024, and dispensed approximately 72,000 bottles to patients Strengthened financial position... ► Artikel lesen | |
01.05. | Tarsus Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
01.05. | Tarsus Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
30.04. | An Overview of Tarsus Pharmaceuticals' Earnings | 2 | Benzinga.com | ||
24.04. | Tarsus Pharmaceuticals, Inc: Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025 | 1 | GlobeNewswire (USA) | ||
22.04. | Tarsus Pharmaceuticals, Inc: Tarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 ... | 1 | GlobeNewswire (USA) | ||
13.03. | Tarsus Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EVOTEC | 6,000 | +0,03 % | Aktien KW 34 Nix passiert? Montag Powell Schub? Aber: Woher die guten Nachrichten? Nvdia am Mittwoch als Lackmustest? Märkte heissgelaufen? News. Rheinmetall. Evotec. Stratec. YOC. Doc Morris. SFC Energy. Multitude. Circus. Delignit. Lang und Schwarz. Kap | Aktien: Diese Woche hnadelte der Markt in einer engen Range von unter 300 Punkten. Schien alles auf Powell's Rede zu warten. Und für die Bullen scheint es sich gelohnt zu haben, die Auguren deuteten... ► Artikel lesen | |
MODERNA | 20,610 | +0,12 % | Moderna, Inc.: Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccines Targeting LP.8.1 Variant of SARS-CoV-2 | CAMBRIDGE, MA / ACCESS Newswire / August 27, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Applications... ► Artikel lesen | |
VIKING THERAPEUTICS | 23,140 | +0,04 % | Why Viking Therapeutics Stock Popped Nearly 4% Today | ||
SCORPIUS | 0,072 | 0,00 % | Scorpius Holdings, Inc.: Scorpius Holdings Announces Corporate Update Including Cost Optimization Initiatives, Strategic Corporate Developments, and Potential Opportunities for Expansion into Southeast Asia | Operational Realignment Expected to Deliver Over $6 Million in Annual Cost Savings Company Exploring CDMO Expansion Opportunities in Southeast Asia San Antonio, TX, May 04, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
KUROS BIOSCIENCES | 26,580 | +0,38 % | Kuros erzielt im ersten Semester erstmals operativen Gewinn | Schlieren - Das Biotechunternehmen Kuros hat den Umsatz im ersten Semester erneut deutlich erhöht und erstmals einen operativen Gewinn erzielt. Getragen wurde die Entwicklung erneut durch das Knochenersatzprodukt... ► Artikel lesen | |
ABIVAX | 68,70 | -0,29 % | Abivax, CRISPR Therapeutics und Revolution Medicines: Biotech im Höhenflug - das wikifolio ... | ||
RELIEF THERAPEUTICS | 2,870 | 0,00 % | Relief Therapeutics erzielt leicht weniger Verlust im ersten Halbjahr | Genf - Das Biotechunternehmen Relief Therapeutics hat im ersten Halbjahr 2025 leicht weniger Verlust geschrieben. Die liquiden Mittel erhöhten sich gegenüber Ende 2024. Die gesamten Einnahmen verringerten... ► Artikel lesen | |
IOVANCE BIOTHERAPEUTICS | 1,888 | -0,73 % | IOVANCE BIOTHERAPEUTICS, INC. - 8-K, Current Report | ||
DENALI THERAPEUTICS | 13,000 | -0,50 % | Denali Therapeutics Inc.: Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights | Tividenofusp alfa BLA for Hunter syndrome accepted for priority review and assigned PDUFA target action date of January 5, 2026; company preparing for commercial launchDNL126 accelerated approval... ► Artikel lesen | |
CYTOMX THERAPEUTICS | 1,706 | -2,40 % | CytomX: Wie geht's hier jetzt weiter? | Die Immuntherapie gegen Krebs entwickelt sich stetig weiter, und CytomX Therapeutics gehört zu den Unternehmen, die mit innovativen Ansätzen neue Maßstäbe setzen wollen. Die sogenannte "Probody"-Technologie... ► Artikel lesen | |
ROCKET PHARMACEUTICALS | 2,799 | -0,32 % | Rocket Pharmaceuticals announces CFO resignation | ||
SYNDAX PHARMACEUTICALS | 13,800 | -1,43 % | Syndax Pharmaceuticals, Inc.: Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on August... ► Artikel lesen | |
ASCENDIS PHARMA | 170,00 | +2,41 % | Ascendis Pharma: New 3-Year Phase 3 Data Confirmed Sustained Response to TransCon PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism, Including Improvements in Biochemistries, Kidney Function, and Quality ... | COPENHAGEN, Denmark, July 14, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from Week 156 of its Phase 3 PaTHway Trial confirming that long-term treatment with... ► Artikel lesen | |
ARCUTIS BIOTHERAPEUTICS | 15,520 | +0,19 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WESTLAKE VILLAGE, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations... ► Artikel lesen | |
JASPER THERAPEUTICS | 2,800 | -1,41 % | Jasper Therapeutics, Inc.: Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update | REDWOOD CITY, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody... ► Artikel lesen |